The lymph as a pool of self-antigens

Trends in Immunology

Volumn 32, Issue 1, 2011, Pages 6-11

  Clement, Cristina C ^a   Rotzschke, Olaf ^b   Santambrogio, Laura ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PROTEIN;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CIRCULATION; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPH; LYMPH NODE; LYMPHATIC SYSTEM; MACROPHAGE; NONHUMAN; PROTEIN PROCESSING; PROTEOMICS; SHORT SURVEY;

ANIMALS; AUTOANTIGENS; HUMANS; IMMUNE TOLERANCE; LYMPH; LYMPHATIC SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDES; PROTEOME;

EID: 78650719866     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2010.10.004     Document Type: Short Survey

References (63)

1. Heim W.J. On the Chemical Composition of lymph from subcutaneous vessels 1932, Harvard University Press, Cambridge, Mass, 553-558.
2. Yoffey J., et al. Lymphatics, Lymph, and Lymphoid tissue 1956, Harvard University Press, Cambridge, Mass.
3. Levick J.R., Michel C.C. Microvascular fluid exchange and the revised Starling principle. Cardiovasc. Res. 2010, 87:198-210.
4. Aukland K., et al. Protein concentration of lymph and interstitial fluid in the rat tail. Am. J. Physiol. 1984, 247:4-9.
5. Leak L.V., et al. Proteomic analysis of lymph. Proteomics 2004, 4:753-765.
6. Interewicz B., et al. Profiling of normal human leg lymph proteins using the 2-D electrophoresis and SELDI-TOF mass spectrophotometry approach. Lymphology 2004, 37:65-72.
7. Nanjee M.N., et al. Lipid and apolipoprotein concentrations in prenodal leg lymph of fasted humans. Associations with plasma concentrations in normal subjects, lipoprotein lipase deficiency, and LCAT deficiency. J. Lipid Res. 2000, 41:1317-1327.
8. Laurent G.J. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am. J. Physiol. 1987, 252:C1-9.
9. Reed R.K., et al. Lymphatic hyaluronan flux from skin increases during increased lymph flow induced by intravenous saline loading. Int. J. Microcirc. Clin. Exp. 1994, 14:56-61.
10. Olszewski W.L., et al. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis & Rheumatism 2001, 44:541-549.
11. Clement C.C., et al. An expanded self-antigen peptidome is carried by the human lymph as compared to the plasma. PLoS ONE 2010, 5:1-10.
12. Lammermann T., Sixt M. The microanatomy of T-cell responses. Immunol. Rev. 2008, 221:26-43.
13. Ingulli E., et al. In situ analysis reveals physical interactions between CD1 1b+ dendritic cells and antigen-specific CD4 T cells after subcutaneous injection of antigen. J. Immunol. 2002, 169:2247-2252.
14. Itano A.A., Jenkins M.K. Antigen presentation to naive CD4 T cells in the lymph node. Nat. Immunol. 2003, 8:733-739.
15. Sixt M., et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 2005, 22:19-29.
16. Gretz J.E., et al. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol. Rev. 1997, 156:11-24.
17. Kaldjian E.P., et al. Spatial and molecular organization of lymph node T cell cortex: a labyrinthine cavity bounded by an epithelium-like monolayer of fibroblastic reticular cells anchored to basement membrane-like extracellular matrix. Int. Immunol. 2001, 13:1243-1253.
18. Roozendaal R., et al. Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 2009, 30:264-276.
19. Iannacone, et al. Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature. 2010, 465:1079-1083.
20. Goldfinch G.M., et al. The proteome of gastric lymph in normal and nematode infected sheep Proteomics 2008, 8:1909-1918.
21. Mittal, A. et al. (2009) The Proteome of Mesenteric Lymph During Acute Pancreatitis and Implications for Treatment JOP. JPancreas (Online) 10, 130-142.
22. Olszewski W.L. Human afferent lymph contains apoptotic cells and " free" apoptotic DNA fragments. Lymphology 2001, 34:179-183.
23. Pang B., et al. Direct antigen presentation and gap junction mediated cross-presentation during apoptosis. J. Immunol. 2009, 183:1083-1090.
24. Honey K., Rudensky A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 2003, 3:472-482.
25. Badylak S.F., et al. Extracellular matrix as a biological scaffold material: Structure and function. Acta Biomater. 2009, 5:1-13.
26. Dustin M.L., de Fougerolles A.R. Reprogramming T cells: the role of extracellular matrix in coordination of T cell activation and migration. Curr. Opin. Immunol. 2001, 3:286-290.
27. Cauwe B., et al. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev in Biochem. Mol. Biol. 2009, 42:113-185.
28. Reiss, K. and Saftig, P. (2009). The " A Disintegrin And Metalloprotease" (ADAM) family of sheddases: Physiological and cellular functions. Seminars in Cell & Developmental Biology 20, 126-137.
29. Kataoka H. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J. Dermatol. Sci. 2009, 56:148-153.
30. Lai Z.W., et al. Membrane proteomics: the development of diagnostics based on protein shedding. Curr. Opin. Mol. Ther. 2009, 11:623-631.
31. Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. Semin. Cell Dev. Biol. 2009, 20:138-145.
32. Heinrich J., Wiegert T. Regulated intramembrane proteolysis in the control of extracytoplasmic function sigma factors. Res. Microbiol. 2009, 160:696-703.
33. Savina A., Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol. Rev. 2007, 219:143-156.
34. Vermaelen K.Y., et al. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J. Exp. Med. 2001, 193:51-60.
35. Cavanagh L.L., Von Andrian U.H. Travellers in many guises: the origins and destinations of dendritic cells. Immunol. Cell. Biol. 2002, 80:448-462.
36. Forster R., et al. CCR7 and its ligands: balancing immunity and tolerance Nat. Rev. Immunol. 2008, 8:362-371.
37. Mathis D., Benoist C. Ann. Rev. Immunol. 2009, 27:287-312.
38. Rock K.L., Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 2005, 207:166-183.
39. Belizaire R., Unanue E.R. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17463-17468.
40. De Bruijn M.L., et al. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur. J. Immunol. 1991, 12:2963-2970.
41. Santambrogio L., et al. Abundant Empty Class II MHC Molecules on the Surface of Immature Dendritic Cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:15050-15055.
42. Venkatraman P., et al. Fluorogenic probes for monitoring peptide binding to class IIMHC proteins in living cells. Nat. Chem. Biol. 2007, 3:222-228.
43. Rabinowitz J.D., et al. Formation of a highly peptide-receptive state of class II MHC. Immunity 1998, 9:699-709.
44. Rock K.L., et al. Dissociation of beta 2-microglobulin leads to the accumulation of a substantial pool of inactive class I MHC heavy chains on the cell surface. Cell 1991, 65:611-620.
45. Pinet V., et al. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen. J. Immunol. 1994, 152:4852-4860.
46. Potolicchio I., et al. Conformational variation of surface class II MHC proteins during myeloid dendritic cell differentiation accompanies structural changes in lysosomal MIIC. J. Immunol. 2005, 175:4935-4947.
47. Natarajan S.K., et al. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J. Immunol. 1999, 162:4030-4036.
48. Reich Z., et al. Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2495-2500.
49. Runnels H.A., et al. Intact proteins can bind to class II histocompatibility molecules with high affinity. Mol. Immunol. 1997, 34:471-480.
50. Denzin L.K., et al. Right place, right time, right peptide: DO keep DM focused. Immunol. Rev. 2005, 207:279-292.
51. Jensen P.E. Antigen processing: HLA-DO--a hitchhiking inhibitor of HLA-DM. Curr. Biol. 1998, 8:128-131.
52. Busch R., et al. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol. Rev. 2005, 207:242-260.
53. Santambrogio L., et al. Extracellular antigen processing and presentation by immature dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:15056-15061.
54. Hopner S., et al. Small organic compounds enhance antigen loading of class II major histocompatibility complex proteins by targeting the polymorphic P1 pocket. J. Biol. Chem. 2006, 281:38535-38542.
55. Falk K., et al. Ligand exchange of major histocompatability complex class II proteins is triggered by H-bond donor groups of small molecules. J. Biol. Chem. 2002, 277:2709-2715.
56. Chou C.L., et al. Short peptide sequences mimic HLA-DM functions. Mol. Immunol. 2008, 45:1935-1943.
57. Marin-Esteban V., et al. Chemical analogues of HLA-DM can induce a peptide-receptive state in HLA-DR molecules. J. Biol. Chem. 2004, 279:50684-50690.
58. Larche M., Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 2005, 11:S69-76.
59. Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 2008, 5:351-360.
60. Ali F.R., Larche M. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert. Rev. Vaccines 2005, 4:881-889.
61. Santamaria P. The long and winding road to understanding and conquering type 1 diabetes. Immunity 2010, 32:437-441.
62. Campbell J.D., et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J. Exp. Med. 2009, 206:1535-1547.
63. Hochweller, et al. Immunological tolerance using synthetic peptides--basic mechanisms and clinical application. Curr. Mol. Med. 2006, 6:631-643.